CYAN
Cyanotech Corporation [CYAN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYAN Stock Summary
In the News
CYAN Financial details
Company Rating
Neutral
Market Cap
2.27M
Income
-4.62M
Revenue
22.49M
Book val./share
2.11
Cash/share
0.1
Dividend
-
Dividend %
-
Employees
86
Optionable
No
Shortable
Yes
Earnings
10 Feb 2024
P/E
-1.37
Forward P/E
-
PEG
0.04
P/S
0.26
P/B
0.4
P/C
3.3
P/FCF
-88.63
Quick Ratio
0.31
Current Ratio
1.46
Debt / Equity
0.81
LT Debt / Equity
0.35
-
-
EPS (TTM)
-0.74
EPS next Y
-
EPS next Q
-
EPS this Y
-257.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-2.37%
Revenue last 5Y
-5.16%
Revenue Q/Q
-12.41%
EPS Q/Q
23.08%
-
-
-
-
SMA20
9.68%
SMA50
-59.04%
SMA100
-53.42%
Inst Own
2.78%
Inst Trans
0.46%
ROA
-15%
ROE
-26%
ROC
-0.18%
Gross Margin
30%
Oper. Margin
-15%
Profit Margin
-18%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.12-1.16
52W High
-
52W Low
-
RSI
48.12
Rel Volume
-
Avg Volume
25.2K
Volume
Perf Week
13.79%
Perf Month
10%
Perf Quarter
-57.68%
Perf Half Y
-56.49%
-
-
-
-
Beta
0.281
-
-
Volatility
0.02%, 0.04%
Prev Close
0%
Price
0.33
Change
0%
CYAN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.21 | 5.36 | 5.33 | 5.84 | 3.71 | |
| Net income per share | -0.62 | 0.06 | 0.15 | 0.35 | -0.55 | |
| Operating cash flow per share | -0.15 | 0.21 | 0.4 | 0.39 | -0.34 | |
| Free cash flow per share | -0.22 | 0.17 | 0.27 | 0.18 | -0.51 | |
| Cash per share | 0.14 | 0.41 | 0.62 | 0.42 | 0.16 | |
| Book value per share | 2.57 | 2.66 | 2.81 | 3.17 | 2.62 | |
| Tangible book value per share | 2.57 | 2.66 | 2.81 | 3.17 | 2.62 | |
| Share holders equity per share | 2.57 | 2.66 | 2.81 | 3.17 | 2.62 | |
| Interest debt per share | 1.5 | 2.22 | 1.83 | 1.46 | 1.87 | |
| Market cap | 18.88M | 12.27M | 20.03M | 20.75M | 5.48M | |
| Enterprise value | 26.16M | 22.43M | 26.82M | 26.77M | 15.67M | |
| P/E ratio | -5.25 | 31.7 | 21.77 | 9.63 | -1.59 | |
| Price to sales ratio | 0.63 | 0.38 | 0.62 | 0.58 | 0.24 | |
| POCF ratio | -22.29 | 9.87 | 8.35 | 8.72 | -2.61 | |
| PFCF ratio | -14.77 | 12.04 | 12.21 | 18.71 | -1.73 | |
| P/B Ratio | 1.27 | 0.77 | 1.18 | 1.06 | 0.34 | |
| PTB ratio | 1.27 | 0.77 | 1.18 | 1.06 | 0.34 | |
| EV to sales | 0.87 | 0.7 | 0.83 | 0.74 | 0.68 | |
| Enterprise value over EBITDA | -24.02 | 6.84 | 12.48 | 5.95 | -18.99 | |
| EV to operating cash flow | -30.89 | 18.04 | 11.17 | 11.25 | -7.46 | |
| EV to free cash flow | -20.47 | 22.01 | 16.35 | 24.13 | -4.95 | |
| Earnings yield | -0.19 | 0.03 | 0.05 | 0.1 | -0.63 | |
| Free cash flow yield | -0.07 | 0.08 | 0.08 | 0.05 | -0.58 | |
| Debt to equity | 0.54 | 0.79 | 0.62 | 0.44 | 0.68 | |
| Debt to assets | 0.27 | 0.4 | 0.34 | 0.27 | 0.38 | |
| Net debt to EBITDA | -6.69 | 3.1 | 3.16 | 1.34 | -12.36 | |
| Current ratio | 1.54 | 2.32 | 2.6 | 3.37 | 1.67 | |
| Interest coverage | -5.15 | 1.6 | 0.15 | 6.57 | -5.82 | |
| Income quality | 0.24 | 3.21 | 2.61 | 1.1 | 0.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.01 | 0.08 | 0.01 | 0 | 0 | |
| Sales general and administrative to revenue | 0.19 | 0.17 | 0.15 | 0.15 | 0.2 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.51 | -0.18 | -0.32 | -0.53 | 0.51 | |
| Capex to revenue | -0.01 | -0.01 | -0.02 | -0.04 | -0.05 | |
| Capex to depreciation | -0.23 | -0.1 | -0.37 | -0.66 | -0.51 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Graham number | 5.99 | 1.97 | 3.09 | 4.99 | 5.7 | |
| ROIC | -0.13 | 0.03 | 0 | 0.08 | -0.09 | |
| Return on tangible assets | -0.12 | 0.01 | 0.03 | 0.07 | -0.12 | |
| Graham Net | -1.16 | -1.19 | -0.66 | -0.4 | -0.97 | |
| Working capital | 5.1M | 8.37M | 9.3M | 11.44M | 5.39M | |
| Tangible asset value | 14.91M | 15.85M | 17.04M | 19.49M | 16.35M | |
| Net current asset value | -125K | -1.21M | 1.27M | 3.71M | 115K | |
| Invested capital | 0.54 | 0.79 | 0.62 | 0.44 | 0.68 | |
| Average receivables | 2.32M | 2.07M | 2.3M | 3.05M | 2.5M | |
| Average payables | 4.22M | 3.53M | 2.21M | 2.32M | 1.69M | |
| Average inventory | 10.15M | 10.46M | 9.03M | 8.94M | 10.09M | |
| Days sales outstanding | 23.95 | 24.65 | 27.49 | 37.18 | 20.96 | |
| Days payables outstanding | 91.03 | 40.63 | 39.32 | 38.48 | 23.41 | |
| Days of inventory on hand | 208.5 | 183.52 | 144.69 | 154.23 | 245.5 | |
| Receivables turnover | 15.24 | 14.81 | 13.28 | 9.82 | 17.41 | |
| Payables turnover | 4.01 | 8.98 | 9.28 | 9.48 | 15.59 | |
| Inventory turnover | 1.75 | 1.99 | 2.52 | 2.37 | 1.49 | |
| ROE | -0.24 | 0.02 | 0.05 | 0.11 | -0.21 | |
| Capex per share | -0.07 | -0.04 | -0.13 | -0.21 | -0.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.99 | 0.87 | 0.83 | 1.04 | 0.85 | |
| Net income per share | -0.1 | -0.23 | -0.22 | -0.13 | -0.16 | |
| Operating cash flow per share | -0.04 | 0.09 | -0.1 | 0.14 | -0.15 | |
| Free cash flow per share | -0.09 | 0.09 | -0.12 | 0.11 | -0.16 | |
| Cash per share | 0.09 | 0.16 | 0.1 | 0.2 | 0.1 | |
| Book value per share | 2.97 | 2.62 | 2.42 | 2.35 | 2.11 | |
| Tangible book value per share | 2.97 | 2.62 | 2.42 | 2.35 | 2.11 | |
| Share holders equity per share | 2.97 | 2.62 | 2.42 | 2.35 | 2.11 | |
| Interest debt per share | 1.69 | 1.82 | 1.87 | 1.86 | 1.74 | |
| Market cap | 6.58M | 5.47M | 5.35M | 4.9M | 5.83M | |
| Enterprise value | 15.99M | 15.66M | 16.18M | 14.93M | 16.38M | |
| P/E ratio | -2.75 | -0.96 | -0.98 | -1.54 | -1.43 | |
| Price to sales ratio | 1.12 | 1.01 | 1.04 | 0.77 | 1.04 | |
| POCF ratio | -29.5 | 9.38 | -8.98 | 5.88 | -5.83 | |
| PFCF ratio | -11.94 | 10.26 | -7.17 | 7.03 | -5.62 | |
| P/B Ratio | 0.37 | 0.33 | 0.36 | 0.34 | 0.42 | |
| PTB ratio | 0.37 | 0.33 | 0.36 | 0.34 | 0.42 | |
| EV to sales | 2.71 | 2.9 | 3.14 | 2.34 | 2.93 | |
| Enterprise value over EBITDA | 139.03 | -21.57 | -23.72 | -140.83 | -49.79 | |
| EV to operating cash flow | -71.7 | 26.86 | -27.14 | 17.9 | -16.38 | |
| EV to free cash flow | -29.02 | 29.38 | -21.68 | 21.39 | -15.8 | |
| Earnings yield | -0.09 | -0.26 | -0.26 | -0.16 | -0.17 | |
| Free cash flow yield | -0.08 | 0.1 | -0.14 | 0.14 | -0.18 | |
| Debt to equity | 0.56 | 0.68 | 0.76 | 0.78 | 0.81 | |
| Debt to assets | 0.33 | 0.38 | 0.39 | 0.4 | 0.41 | |
| Net debt to EBITDA | 81.83 | -14.04 | -15.87 | -94.56 | -32.06 | |
| Current ratio | 3.11 | 1.67 | 1.49 | 1.46 | 1.44 | |
| Interest coverage | -2.17 | -7.42 | -7.56 | -3.88 | -4.93 | |
| Income quality | 0.37 | -0.41 | 0.44 | -1.05 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.17 | 0.19 | 0.25 | 0.18 | 0.17 | |
| Research and developement to revenue | 0.02 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 1.47 | -0.09 | 0.25 | -0.16 | 0.04 | |
| Capex to revenue | -0.06 | -0.01 | -0.03 | -0.02 | -0.01 | |
| Capex to depreciation | -0.63 | -0.09 | -0.28 | -0.26 | -0.07 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | |
| Graham number | 2.58 | 3.68 | 3.46 | 2.62 | 2.72 | |
| ROIC | -0.01 | -0.04 | -0.04 | -0.02 | -0.03 | |
| Return on tangible assets | -0.02 | -0.05 | -0.05 | -0.03 | -0.04 | |
| Graham Net | -0.69 | -0.97 | -1.1 | -1.07 | -1.02 | |
| Working capital | 9.86M | 5.39M | 4.38M | 4.03M | 3.75M | |
| Tangible asset value | 17.73M | 16.35M | 15.04M | 14.41M | 13.83M | |
| Net current asset value | 2.49M | 115K | -766K | -990K | -1.14M | |
| Invested capital | 0.56 | 0.68 | 0.76 | 0.78 | 0.81 | |
| Average receivables | 2.14M | 1.74M | 1.56M | 1.61M | 1.73M | |
| Average payables | 1.29M | 1.03M | 1.37M | 1.56M | 1.39M | |
| Average inventory | 11.83M | 11.14M | 10.61M | 10.05M | 9.36M | |
| Days sales outstanding | 32.94 | 22.22 | 31.38 | 20.19 | 32.83 | |
| Days payables outstanding | 22.48 | 22.94 | 42.86 | 29.24 | 31.78 | |
| Days of inventory on hand | 252.4 | 240.61 | 261.63 | 201.44 | 208.79 | |
| Receivables turnover | 2.73 | 4.05 | 2.87 | 4.46 | 2.74 | |
| Payables turnover | 4 | 3.92 | 2.1 | 3.08 | 2.83 | |
| Inventory turnover | 0.36 | 0.37 | 0.34 | 0.45 | 0.43 | |
| ROE | -0.03 | -0.09 | -0.09 | -0.06 | -0.07 | |
| Capex per share | -0.05 | -0.01 | -0.02 | -0.02 | -0.01 |
CYAN Frequently Asked Questions
What is Cyanotech Corporation stock symbol ?
Cyanotech Corporation is a US stock , located in Kailua-kona of Hi and trading under the symbol CYAN
What is Cyanotech Corporation stock quote today ?
Cyanotech Corporation stock price is $0.33 today.
Is Cyanotech Corporation stock public?
Yes, Cyanotech Corporation is a publicly traded company.
Company Profile
- Volume Average 25.2K
- Market Capitalization 2.27M
- Employee 86
- CEO Mr. Matthew Keith Custer
- Headquarters Kailua-Kona,HI,US
- IPO Date 1991-05-21
-
Website
https://www.cyanotech.com 
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant to enhance skin, and to support eye, joint and immune health, as well as used as a human dietary supplement and dietary ingredient; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, which is used for extra energy, strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. It also provides contract extraction services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health foods, nutraceuticals, and dietary supplement markets. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
